Company news

Rhythm Pharmaceuticals, Inc. news in 2024

Rhythm Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

December 19, 2024

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to in...

December 2, 2024

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

November 17, 2024

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

November 12, 2024

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

November 12, 2024

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

November 4, 2024

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

November 3, 2024

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

October 23, 2024

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

October 22, 2024

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

August 25, 2024

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

August 25, 2024

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

August 5, 2024

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

July 30, 2024

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

July 22, 2024

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

July 22, 2024

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

July 7, 2024

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

June 27, 2024

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

June 2, 2024

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

June 2, 2024

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

May 21, 2024

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

May 6, 2024

Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

May 5, 2024

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

April 28, 2024

Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

April 23, 2024

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

March 31, 2024

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

March 24, 2024

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences

March 5, 2024

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

February 21, 2024

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

February 21, 2024

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

February 6, 2024

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

January 30, 2024

Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

January 3, 2024

Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640

January 3, 2024

Calls in 2024

Decks in 2024